Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

HIGHLIGHTS

• who: Jens Huober from the setting focus on patients that did not experience a pCRTaking the results of the here presented analysis into consideration there is also a group of patients with pCR that have a higher risk of relapse and should therefore be considered for an additional treatment despite pCR in postneoadjuvant studies to improve long-term outcome of this otherwise neglected patient population. PATIENTS AND METHODS Patients Data from the five neoadjuvant trials GeparTrio (NCT00544765) (ethics committee of the University of Frankfurt), GeparQuattro (NCT00288002) (ethics committee of the University of Frankfurt), GeparQuinto (NCT00567554) (ethics committee . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.